Estelle Healy
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Estelle Healy has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Amanda Wallace
Department of Neuromuscular Diseases Institute of Neurology, University College London London UK
1 shared publication - Gita Ramdharry
UCL Queen Square Institute of Neurology University College London London UK
1 shared publication - Henry Houlden
UCL Queen Square Institute of Neurology and the National Hospital for Neurology and Neurosurgery
1 shared publication - Janice L. Holton
Department of Molecular Neuroscience
1 shared publication - Jasper M. Morrow
Department of Neuromuscular Diseases, Queen Square UCL Institute of Neurology, London, UK
1 shared publication - Linda Greensmith
Department of Neuromuscular Diseases, UCL Institute of Neurology, London, UK
1 shared publication
Latest Publications
- Open Access
- 18 November 2014
- Published by Springer Nature in Current Rheumatology Reports
- Vol. 16 (12) , 477
Ongoing Developments in Sporadic Inclusion Body Myositis
Sporadic inclusion body myositis (IBM) is an acquired muscle disorder associated with ageing, for which there is no effective treatment. Ongoing developments include: genetic studies that may provide insights regarding the pathogenesis of IBM, improved histopathological markers, the description of a new IBM autoantibody, scrutiny of the diagnostic utility of clinical features and biomarkers, the refinement of diagnostic criteria, the emerging use of MRI as a diagnostic and monitoring tool, and new pathogenic insights that have led to novel therapeutic approaches being trialled for IBM, including treatments with the objective of restoring protein homeostasis and myostatin blockers. The effect of exercise in IBM continues to be investigated. However, despite these ongoing developments, the aetiopathogenesis of IBM remains uncertain. A translational and multidisciplinary collaborative approach is critical to improve the diagnosis, treatment, and care of patients with IBM.
- 18 November 2014
- Published by Springer Nature in Current Rheumatology Reports
- Vol. 16 (12) , 477
Open AccessOngoing Developments in Sporadic Inclusion Body Myositis
Sporadic inclusion body myositis (IBM) is an acquired muscle disorder associated with ageing, for which there is no effective treatment. Ongoing developments include: genetic studies that may provide insights regarding the pathogenesis of IBM, improved histopathological markers, the description of a new IBM autoantibody, scrutiny of the diagnostic utility of clinical features and biomarkers, the refinement of diagnostic criteria, the emerging use of MRI as a diagnostic and monitoring tool, and new pathogenic insights that have led to novel therapeutic approaches being trialled for IBM, including treatments with the objective of restoring protein homeostasis and myostatin blockers. The effect of exercise in IBM continues to be investigated. However, despite these ongoing developments, the aetiopathogenesis of IBM remains uncertain. A translational and multidisciplinary collaborative approach is critical to improve the diagnosis, treatment, and care of patients with IBM.